Article
ESMO: Novartis posts data from failed spartalizumab phase 3, reaffirms commitment to PD-1 combos
Rating:
0.0
Views:
108
Likes:
1
Library:
1
Novartis has shared data from the failed phase 3 melanoma trial of its anti-PD-1 checkpoint inhibitor spartalizumab. The readout showed adding spartalizumab to Tafinlar and Mekinist achieved similar results to an earlier assessment of a similar combination but on this occasion the difference fell short of statistical significance.
Rate This Post
-
Education
-
Communication
-
Entertainment
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value